glp 1 dementia study The EVOKE trials found that semaglutide, the GLP-1 drug behind several popular diabetes and weight loss medications, did not meaningfully slow cognitive decline in people with Alzheimer's disease. Despite these findings, scientists In New Dementia Trials, Ozempic's

Ghiyam, a longevity physician at Med Pod LA in Beverly Hills who joined the Live Well podcast to break down the peptide boom firsthand, buying from it is essentially Russian roulette

Topical is the more evidence-supported route, especially for skin endpoints

Releases WADAs 2026 Prohibited List is now in force The World Anti-Doping Agency (WADA) wishes to remind stakeholders that the 2026 List of Prohibited Substances and Methods (List) and the 2026 Monitoring Program are now in force as of today (1 January 2026)

T.BittermanK

Epithalon is explored for its influence on chromosomal end protection mechanisms, contributing to investigation of cellular stability pathways

Immunology of psoriasis